Fruit juices as perpetrators of drug interactions: The role of organic aniontransporting polypeptides

Clinical Pharmacology and Therapeutics

Volumn 92, Issue 5, 2012, Pages 622-630

  Dolton, M J ^a   Roufogalis, B D ^a   McLachlan, A J ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ANZAC Research Institute   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ALISKIREN; ATENOLOL; AURANTIIN; CELIPROLOL; CIPROFLOXACIN; CYTOCHROME P450 3A4; EPICATECHIN; FEXOFENADINE; GLIBENCLAMIDE; HESPERETIN; HESPERIDIN; LEVOFLOXACIN; MESSENGER RNA; MONTELUKAST; MULTIDRUG RESISTANCE PROTEIN; NARIRUTIN; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 1; PHLORIZIN; PITAVASTATIN; PRAVASTATIN; REPAGLINIDE; SLCO2B1 PROTEIN; TALINOLOL; THYROXINE; UNCLASSIFIED DRUG;

ALLERGIC RHINITIS; APPLE JUICE; AREA UNDER THE CURVE; ASTHMA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; FOOD DRUG INTERACTION; FOOD INTAKE; GRAPEFRUIT JUICE; HUMAN; HYPERTENSION; INTESTINE CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SMALL INTESTINE;

ADMINISTRATION, ORAL; ANIMALS; BEVERAGES; BIOLOGICAL AVAILABILITY; FOOD-DRUG INTERACTIONS; FRUIT; HUMANS; ORGANIC ANION TRANSPORTERS; PHARMACEUTICAL PREPARATIONS;

EID: 84867886267     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.159     Document Type: Review

References (75)

1. Bailey, D.G., Spence, J.D., Edgar, B., Bayliff, C.D. & Arnold, J.M. Ethanol enhances the hemodynamic effects of felodipine. Clin. Invest. Med. 12, 357-362 (1989). (Pubitemid 20014984)
2. Niemi, M. Role of OATP transporters in the disposition of drugs. Pharmacogenomics 8, 787-802 (2007). (Pubitemid 47288978)
3. Giacomini, K.M. et al. Membrane transporters in drug development. Nat. Rev. Drug Discov. 9, 215-236 (2010).
4. Koenen, A., Kroemer, H.K., Grube, M. & Meyer zu Schwabedissen, H.E. Current understanding of hepatic and intestinal OATP-mediated drug-drug interactions. Expert Rev. Clin. Pharmacol. 4, 729-742 (2011).
5. Dresser, G.K. et al. Fruit juices inhibit organic anion transporting polypeptidemediated drug uptake to decrease the oral availability of fexofenadine. Clin. Pharmacol. Ther. 71, 11-20 (2002). (Pubitemid 34124034)
6. Glaeser, H. et al. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin. Pharmacol. Ther. 81, 362-370 (2007). (Pubitemid 46364477)
7. Bailey, D.G., Dresser, G.K., Leake, B.F. & Kim, R.B. Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. Clin. Pharmacol. Ther. 81, 495-502 (2007). (Pubitemid 46452308)
8. Lilja, J.J., Backman, J.T., Laitila, J., Luurila, H. & Neuvonen, P.J. Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. Clin. Pharmacol. Ther. 73, 192-198 (2003). (Pubitemid 36269670)
9. Tapaninen, T., Neuvonen, P.J. & Niemi, M. Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren. Br. J. Clin. Pharmacol. 71, 718-726 (2011).
10. Lilja, J.J., Raaska, K. & Neuvonen, P.J. Effects of orange juice on the pharmacokinetics of atenolol. Eur. J. Clin. Pharmacol. 61, 337-340 (2005). (Pubitemid 41569306)
11. Nishimura, M. & Naito, S. Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metab. Pharmacokinet. 20, 452-477 (2005).
12. Englund, G. et al. Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur. J. Pharm. Sci. 29, 269-277 (2006). (Pubitemid 44602404)
13. Seithel, A., Karlsson, J., Hilgendorf, C., Björquist, A. & Ungell, A.L. Variability in mRNA expression of ABC-and SLC-transporters in human intestinal cells: comparison between human segments and Caco-2 cells. Eur. J. Pharm. Sci. 28, 291-299 (2006). (Pubitemid 44218740)
14. Hilgendorf, C., Ahlin, G., Seithel, A., Artursson, P., Ungell, A.L. & Karlsson, J. Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab. Dispos. 35, 1333-1340 (2007). (Pubitemid 47121774)
15. Meier, Y. et al. Regional distribution of solute carrier mRNA expression along the human intestinal tract. Drug Metab. Dispos. 35, 590-594 (2007). (Pubitemid 46513261)
16. Ballestero, M.R., Monte, M.J., Briz, O., Jimenez, F., Gonzalez-San Martin, F. & Marin, J.J. Expression of transporters potentially involved in the targeting of cytostatic bile acid derivatives to colon cancer and polyps. Biochem. Pharmacol. 72, 729-738 (2006). (Pubitemid 44233549)
17. Eechoute, K. et al. Environmental and genetic factors affecting transport of imatinib by OATP1A2. Clin. Pharmacol. Ther. 89, 816-820 (2011).
18. Maubon, N. et al. Analysis of drug transporter expression in human intestinal Caco-2 cells by real-time PCR. Fundam. Clin. Pharmacol. 21, 659-663 (2007). (Pubitemid 350151254)
19. Lee, W. et al. Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J. Biol. Chem. 280, 9610-9617 (2005). (Pubitemid 40409657)
20. Franke, R.M., Scherkenbach, L.A. & Sparreboom, A. Pharmacogenetics of the organic anion transporting polypeptide 1A2. Pharmacogenomics 10, 339-344 (2009).
21. Anderson, L. & Seilhamer, J. A comparison of selected mRNA and protein abundances in human liver. Electrophoresis 18, 533-537 (1997). (Pubitemid 27174443)
22. Su, Y., Zhang, X. & Sinko, P.J. Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol. Pharm. 1, 49-56 (2004).
23. Kobayashi, D., Nozawa, T., Imai, K., Nezu, J., Tsuji, A. & Tamai, I. Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J. Pharmacol. Exp. Ther. 306, 703-708 (2003). (Pubitemid 36886171)
24. Lown, K.S. et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J. Clin. Invest. 99, 2545-2553 (1997). (Pubitemid 27227734)
25. Lilja, J.J., Kivistö, K.T. & Neuvonen, P.J. Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin. Clin. Pharmacol. Ther. 68, 384-390 (2000).
26. De Castro, W.V., Mertens-Talcott, S., Rubner, A., Butterweck, V. & Derendorf, H. Variation of flavonoids and furanocoumarins in grapefruit juices: a potential source of variability in grapefruit juice-drug interaction studies. J. Agric. Food Chem. 54, 249-255 (2006). (Pubitemid 43119947)
27. Gattuso, G., Barreca, D., Gargiulli, C., Leuzzi, U. & Caristi, C. Flavonoid composition of Citrus juices. Molecules 12, 1641-1673 (2007).
28. Guo, L.Q., Fukuda, K., Ohta, T. & Yamazoe, Y. Role of furanocoumarin derivatives on grapefruit juice-mediated inhibition of human CYP3A activity. Drug Metab. Dispos. 28, 766-771 (2000). (Pubitemid 30470826)
29. Edwards, D.J. et al. 6',7'-Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein. Clin. Pharmacol. Ther. 65, 237-244 (1999). (Pubitemid 29142929)
30. Rouseff, R.L., Martin, S.F. & Youtsey, C.O. Quantitative survey of narirutin, naringin, hesperidin, and neohesperidin in citrus. J. Agric. Food Chem. 35, 1027-1030 (1987).
31. Satoh, H. et al. Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab. Dispos. 33, 518-523 (2005). (Pubitemid 40393194)
32. Tran, V.H., Marks, D., Duke, R.K., Bebawy, M., Duke, C.C. & Roufogalis, B.D. Modulation of P-glycoprotein-mediated anticancer drug accumulation, cytotoxicity, and ATPase activity by flavonoid interactions. Nutr. Cancer 63, 435-443 (2011).
33. Taipalensuu, J. et al. Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J. Pharmacol. Exp. Ther. 299, 164-170 (2001). (Pubitemid 32905131)
34. Zhang, S., Yang, X. & Morris, M.E. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol. Pharmacol. 65, 1208-1216 (2004). (Pubitemid 38543491)
35. Uesawa, Y. & Mohri, K. Hesperidin in orange juice reduces the absorption of celiprolol in rats. Biopharm. Drug Dispos. 29, 185-188 (2008). (Pubitemid 351722163)
36. Schieber, A., Keller, P. & Carle, R. Determination of phenolic acids and flavonoids of apple and pear by high-performance liquid chromatography. J. Chromatogr. A 910, 265-273 (2001). (Pubitemid 32126294)
37. Van Der Sluis, A.A., Dekker, M., Skrede, G. & Jongen, W.M. Activity and concentration of polyphenolic antioxidants in apple juice. 1. Effect of existing production methods. J. Agric. Food Chem. 50, 7211-7219 (2002). (Pubitemid 35424879)
38. Young, J.F. et al. Effect of fruit juice intake on urinary quercetin excretion and biomarkers of antioxidative status. Am. J. Clin. Nutr. 69, 87-94 (1999). (Pubitemid 29031256)
39. Wang, X., Wolkoff, A.W. & Morris, M.E. Flavonoids as a novel class of human organic anion-transporting polypeptide OATP1B1 (OATP-C) modulators. Drug Metab. Dispos. 33, 1666-1672 (2005). (Pubitemid 41539965)
40. Fuchikami, H., Satoh, H., Tsujimoto, M., Ohdo, S., Ohtani, H. & Sawada, Y. Effects of herbal extracts on the function of human organic anion-transporting polypeptide OATP-B. Drug Metab. Dispos. 34, 577-582 (2006).
41. Mandery, K. et al. Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem. Pharmacol. 80, 1746-1753 (2010).
42. Kim, K.A., Park, P.W. & Park, J.Y. Short-term effect of quercetin on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein, in healthy volunteers. Eur. J. Clin. Pharmacol. 65, 609-614 (2009).
43. Robards, K., Li, X., Antolovich, M. & Boyd, S. Characterisation of citrus by chromatographic analysis of flavonoids. J. Sci. Food Agric. 75, 87-101 (1997). (Pubitemid 27389676)
44. Banfield, C., Gupta, S., Marino, M., Lim, J. & Affrime, M. Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine. Clin. Pharmacokinet. 41, 311-318 (2002). (Pubitemid 34533758)
45. Dresser, G.K., Kim, R.B. & Bailey, D.G. Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides. Clin. Pharmacol. Ther. 77, 170-177 (2005). (Pubitemid 40269132)
46. Imanaga, J. et al. The effects of the SLCO2B1 c.1457C > T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans. Pharmacogenet. Genomics 21, 84-93 (2011).
47. Nozawa, T., Imai, K., Nezu, J., Tsuji, A. & Tamai, I. Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J. Pharmacol. Exp. Ther. 308, 438-445 (2004). (Pubitemid 38134202)
48. Schwarz, U.I. et al. Grapefruit juice ingestion significantly reduces talinolol bioavailability. Clin. Pharmacol. Ther. 77, 291-301 (2005). (Pubitemid 40470385)
49. Lilja, J.J., Juntti-Patinen, L. & Neuvonen, P.J. Orange juice substantially reduces the bioavailability of the beta-adrenergic-blocking agent celiprolol. Clin. Pharmacol. Ther. 75, 184-190 (2004). (Pubitemid 38314867)
50. Ieiri, I. et al. Microdosing clinical study: pharmacokinetic, pharmacogenomic (SLCO2B1), and interaction (grapefruit juice) profiles of celiprolol following the oral microdose and therapeutic dose. J. Clin. Pharmacol. 52, 1078-1089 (2012).
51. Jeon, H.et al. Apple juice greatly reduces systemic exposure to atenolol. Br. J. Clin. Pharmacol. (2012), e-pub ahead of print 11 May 2012.
52. Kato, Y., Miyazaki, T., Kano, T., Sugiura, T., Kubo, Y. & Tsuji, A. Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol. J. Pharm. Sci. 98, 2529-2539 (2009).
53. Shirasaka, Y., Kuraoka, E., Spahn-Langguth, H., Nakanishi, T., Langguth, P. & Tamai, I. Species difference in the effect of grapefruit juice on intestinal absorption of talinolol between human and rat. J. Pharmacol. Exp. Ther. 332, 181-189 (2010).
54. Forrest, A., Nix, D.E., Ballow, C.H., Goss, T.F., Birmingham, M.C. & Schentag, J.J. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37, 1073-1081 (1993). (Pubitemid 23141323)
55. Neuhofel, A.L., Wilton, J.H., Victory, J.M., Hejmanowsk, L.G. & Amsden, G.W. Lack of bioequivalence of ciprofloxacin when administered with calcium-fortified orange juice: a new twist on an old interaction. J. Clin. Pharmacol. 42, 461-466 (2002). (Pubitemid 34259781)
56. Maeda, T. et al. Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol. Pharm. 4, 85-94 (2007).
57. Haeseker, M. et al. The ciprofloxacin target AUC/MIC ratio is not reached in hospitalized patients with the recommended dosing regimens. Br. J. Clin. Pharmacol. (2012), e-pub ahead of print 23 May 2012.
58. Thomas, J.K. et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob. Agents Chemother. 42, 521-527 (1998). (Pubitemid 28114802)
59. Mougey, E.B., Feng, H., Castro, M., Irvin, C.G. & Lima, J.J. Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet. Genomics 19, 129-138 (2009).
60. Malmstrom, K. et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/ Beclomethasone Study Group. Ann. Intern. Med. 130, 487-495 (1999). (Pubitemid 29135801)
61. Meltzer, E.O. et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. J. Allergy Clin. Immunol. 105, 917-922 (2000). (Pubitemid 30324400)
62. Mougey, E.B., Lang, J.E., Wen, X. & Lima, J.J. Effect of citrus juice and SLCO2B1 genotype on the pharmacokinetics of montelukast. J. Clin. Pharmacol. 51, 751-760 (2011).
63. Gradman, A.H., Schmieder, R.E., Lins, R.L., Nussberger, J., Chiang, Y. & Bedigian, M.P. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 111, 1012-1018 (2005). (Pubitemid 40354519)
64. Vaidyanathan, S. et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren. J. Clin. Pharmacol. 48, 1323-1338 (2008).
65. Rebello, S. et al. Intestinal OATP1A2 inhibition as a potential mechanism for the effect of grapefruit juice on aliskiren pharmacokinetics in healthy subjects. Eur. J. Clin. Pharmacol. 68, 697-708 (2012).
66. Vaidyanathan, S., Jarugula, V., Dieterich, H.A., Howard, D. & Dole, W.P. Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin. Pharmacokinet. 47, 515-531 (2008). (Pubitemid 351969826)
67. Wood, J.M. et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem. Biophys. Res. Commun. 308, 698-705 (2003). (Pubitemid 36976519)
68. Tapaninen, T., Neuvonen, P.J. & Niemi, M. Grapefruit juice greatly reduces the plasma concentrations of the OATP2B1 and CYP3A4 substrate aliskiren. Clin. Pharmacol. Ther. 88, 339-342 (2010).
69. Lilja, J.J., Raaska, K. & Neuvonen, P.J. Effects of grapefruit juice on the pharmacokinetics of acebutolol. Br. J. Clin. Pharmacol. 60, 659-663 (2005). (Pubitemid 41705387)
70. Lilja, J.J., Niemi, M., Fredrikson, H. & Neuvonen, P.J. Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide. Br. J. Clin. Pharmacol. 63, 732-740 (2007). (Pubitemid 46753573)
71. Wallace, A.W., Victory, J.M. & Amsden, G.W. Lack of bioequivalence when levofloxacin and calcium-fortified orange juice are coadministered to healthy volunteers. J. Clin. Pharmacol. 43, 539-544 (2003). (Pubitemid 36506155)
72. Lilja, J.J., Laitinen, K. & Neuvonen, P.J. Effects of grapefruit juice on the absorption of levothyroxine. Br. J. Clin. Pharmacol. 60, 337-341 (2005). (Pubitemid 41224144)
73. Ando, H. et al. Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. Br. J. Clin. Pharmacol. 60, 494-497 (2005). (Pubitemid 41532449)
74. Lilja, J.J., Kivistö, K.T. & Neuvonen, P.J. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin. Pharmacol. Ther. 66, 118-127 (1999). (Pubitemid 29398847)
75. Fukazawa, I., Uchida, N., Uchida, E. & Yasuhara, H. Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese. Br. J. Clin. Pharmacol. 57, 448-455 (2004). (Pubitemid 38519650)